Impact of Molecular Testing on the Management of Indeterminate Thyroid Nodules Among Western and Asian Countries: a Systematic Review and Meta-analysis.

Published on Aug 7, 2020in Endocrine Pathology3.168
· DOI :10.1007/S12022-020-09643-0
Hanh T T Ngo5
Estimated H-index: 5
(Ho Chi Minh City Medicine and Pharmacy University),
Hanh Thi Tuyet Ngo1
Estimated H-index: 1
+ 4 AuthorsHuy Gia Vuong1
Estimated H-index: 1
(OU: University of Oklahoma)
Sources
Abstract
Molecular testing has a potential to improve the management of patients with indeterminate thyroid nodules considered for surgery. This study examined the influence of molecular tests on the treatment of indeterminate nodules, particularly the differences between Western and Asian countries. Electronic databases including PubMed and Web of Science were searched for relevant articles from 2010 to March 2019. We computed meta-analysis of proportion and their 95% confidence intervals (CIs) utilizing the random-effect model. We used independent samples t test to compare the resection rate (RR), rate of malignancy (ROM), rate of preoperative molecular testing (RMT), and rate of positive test (RP) between subgroups. We included a total of 34 studies with 7976 indeterminate nodules. The multigene panel testing methods were exclusively used in the USA. Compared with the non-molecular era, molecular testing was associated with a significantly increased ROM (47.9% versus 32.1%; p = 0.001). The ROM of indeterminate nodules in Asian institutes was significantly higher than that in Western countries (75.3% versus 36.6%; p < 0.001, respectively). Institutes employing single-gene tests achieved a higher ROM (59.8% versus 37.9%; p = 0.013). Molecular testing is a promising method to tailor the clinical management for indeterminate thyroid FNA. Certain differences in routine thyroid cytopathology practice among the West and the East are still present. The combination of molecular testing and active surveillance enhances the accuracy of case selection for surgery in Asian countries.
📖 Papers frequently viewed together
10 Citations
26 Citations
References68
Newest
#1Huy Gia Vuong (University of Yamanashi)H-Index: 15
#2Hanh Thi Tuyet NgoH-Index: 1
Last. Tetsuo Kondo (University of Yamanashi)H-Index: 27
view all 8 authors...
There is increasing evidence showing that clinicians employ different management strategies in their use of The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC). In this meta-analysis, we investigated the differences in diagnosis frequency, resection rate (RR), and risk of malignancy (ROM) between Western (ie, American and European) and Asian cytopathology practices. We searched PubMed and Web of Science from January 2010 to January 2019. Proportion and 95% CIs were calculated using ...
22 CitationsSource
#1David N. Poller (QA: Queen Alexandra Hospital)H-Index: 28
#2Massimo Bongiovanni (Synlab Group)H-Index: 32
Last. Pierpaolo Trimboli (Hospital Authority)H-Index: 1
view all 3 authors...
BACKGROUND: The UK Royal College of Pathologists Thy terminology for reporting thyroid fine-needle aspiration cytology (FNAC), first published in 2009 is used throughout the United Kingdom and Ireland, in some parts of Italy and Switzerland and elsewhere. There is no review of the literature or meta-analysis of the risk of malignancy (ROM) in the various categories of the UK Thy terminology. The goal of this study was to establish the published ROM for each Thy category and compare the results w...
12 CitationsSource
#1Kennichi Kakudo (Wakayama Medical University)H-Index: 33
#1Kennichi Kakudo (Wakayama Medical University)H-Index: 33
Last. Priyanthi Kumarasinghe (UWA: University of Western Australia)H-Index: 4
view all 5 authors...
11 CitationsSource
Importance In the United States, the most used molecular test for the evaluation of cytologically indeterminate thyroid nodules is the Afirma gene expression classifier (GEC). Objective To evaluate the GEC’s diagnostic performance through a novel approach to assess whether the findings of the initial validation study are consistent with the results of postmarketing studies. Data Sources PubMed was systematically searched from inception through October 26, 2017, using the termsgene expression cla...
10 CitationsSource
#1Mayumi Endo (OSU: Ohio State University)H-Index: 2
#2Fadi Nabhan (OSU: Ohio State University)H-Index: 10
Last. Jennifer A. Sipos (OSU: Ohio State University)H-Index: 13
view all 14 authors...
Background: The Afirma Gene Expression Classifier (GEC) has been used to further characterize cytologically indeterminate (cyto-I) thyroid nodules into either benign or suspicious categories. Howev...
30 CitationsSource
#1Massimo Bongiovanni (UNIL: University of Lausanne)H-Index: 32
#2William C. Faquin (Harvard University)H-Index: 68
Last. Pierpaolo TrimboliH-Index: 30
view all 6 authors...
OBJECTIVE: The second version of the Bethesda System for Reporting Thyroid Cytopathology endorsed the introduction of non-invasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP) as a distinct entity with low malignant potential into clinical practice. Consequently, the risk of malignancy (ROM) of cytological diagnoses has changed, but the magnitude of the change remains uncertain. The present systematic review was undertaken to obtain more robust information about the ...
13 CitationsSource
#1Massimo Bongiovanni (UNIL: University of Lausanne)H-Index: 32
#2Luca GiovanellaH-Index: 46
Last. Pierpaolo TrimboliH-Index: 30
view all 4 authors...
Background: The recent introduction of noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP) in the World Health Organization classification of thyroid tumors has si...
23 CitationsSource
#1Pierpaolo TrimboliH-Index: 30
#2Anna CrescenziH-Index: 30
Last. Massimo Bongiovanni (UNIL: University of Lausanne)H-Index: 32
view all 6 authors...
Background Italian consensus for the classification and reporting of thyroid cytology has proposed to discriminate the cancer prevalence of high (Tir 3B) vs. low (Tir 3A) risk indeterminate nodules. To obtain more robust evidence on this topic, we performed a meta-analysis of the Odds Ratio (OR) of malignancy of Tir 3B vs. Tir 3A nodules.
17 CitationsSource
#1N. Paul Ohori (University of Pittsburgh)H-Index: 33
#2Michael S. Landau (University of Pittsburgh)H-Index: 10
Last. Yuri E. Nikiforov (University of Pittsburgh)H-Index: 90
view all 10 authors...
BACKGROUND: The benign call rate (BCR) is the percentage of cytomorphologically indeterminate cases with subsequent benign or negative molecular results. For rule-out tests, the BCR is an important parameter because these molecular "negative" cases may be managed similarly to those with a benign cytology diagnosis. Although earlier versions of ThyroSeq molecular tests were less effective in excluding malignancy, the extensively expanded v3 version with a high negative predictive value is conside...
12 CitationsSource
#1Huy Gia VuongH-Index: 15
#2Thao T. K. TranH-Index: 2
Last. Tetsuo KondoH-Index: 27
view all 8 authors...
ABSTRACT Introduction It is still controversial as to how the reclassification of non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) affects the risk of malignancy (ROM) in The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC). This meta-analysis was aimed to investigate the impact of NIFTP on the ROM in each TBSRTC category. Methods We accessed three electronic databases including PubMed, Web of Science, and Scopus to search for relevant data from J...
17 CitationsSource
Cited By0
Newest
#1Michiya NishinoH-Index: 15
#2Claudio BellevicineH-Index: 23
Last. Zubair W. BalochH-Index: 71
view all 3 authors...
The past decade has witnessed significant advances in the application of molecular diagnostics for the pre-operative risk-stratification of cytologically indeterminate thyroid nodules. The tests that are currently marketed in the United States for this purpose combine aspects of tumor genotyping with gene and/or microRNA expression profiling. This review compares the general methodology and clinical validation studies for the three tests currently offered in the United States: ThyroSeq v3, Afirm...
Source